Literature DB >> 11389995

Tumor targeting with surface-shielded ligand--polycation DNA complexes.

R Kircheis1, T Blessing, S Brunner, L Wightman, E Wagner.   

Abstract

Incorporation of the receptor binding ligands transferrin (Tf) or epidermal growth factor (EGF) into DNA/polyethylenimine (PEI) complexes was found to enhance gene transfer into tumor cell lines in a receptor-dependent manner. In systemic applications, the surface charge of DNA complexes dominated the in vivo characteristics of gene transfer. Administration of surface-shielded Tf-polycation/DNA complexes into the tail vein of A/J mice resulted in preferential gene delivery into distantly growing subcutaneous Neuro2a tumors. In contrast, application of positively charged DNA/PEI complexes directed gene transfer primarily to the lung. Two alternatives of masking the surface charge of complexes were accomplished. In the first case, shielding was obtained by covalently coating of DNA/Tf-PEI complexes with polyethylene glycol (PEG). Alternatively, incorporation of sufficient Tf protein into the DNA complexes resulted in charge shielding even without PEGylation. In the latter case lower-molecular weight polycations (25 kDa PEI for Tf-PEI complexes, or 32 kDa polylysine for AVET complexes) were used.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11389995     DOI: 10.1016/s0168-3659(01)00272-3

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  18 in total

1.  Structural and functional consequences of poly(ethylene glycol) inclusion on DNA condensation for gene delivery.

Authors:  Peter G Millili; Joshua A Selekman; Kory M Blocker; David A Johnson; Ulhas P Naik; Millicent O Sullivan
Journal:  Microsc Res Tech       Date:  2010-09       Impact factor: 2.769

Review 2.  Applying horizontal gene transfer phenomena to enhance non-viral gene therapy.

Authors:  Jacob J Elmer; Matthew D Christensen; Kaushal Rege
Journal:  J Control Release       Date:  2013-08-30       Impact factor: 9.776

Review 3.  Polymeric nanogel formulations of nucleoside analogs.

Authors:  Serguei V Vinogradov
Journal:  Expert Opin Drug Deliv       Date:  2007-01       Impact factor: 6.648

Review 4.  Strategies to improve drug delivery across the blood-brain barrier.

Authors:  Albertus G de Boer; Pieter J Gaillard
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

5.  Diseases originate and terminate by genes: unraveling nonviral gene delivery.

Authors:  Rajan Swami; Indu Singh; Wahid Khan; Sistla Ramakrishna
Journal:  Drug Deliv Transl Res       Date:  2013-12       Impact factor: 4.617

6.  Systemic delivery of siRNA nanoparticles targeting RRM2 suppresses head and neck tumor growth.

Authors:  Mohammad Aminur Rahman; A R M Ruhul Amin; Xu Wang; Jonathan E Zuckerman; Chung Hang J Choi; Bingsen Zhou; Dongsheng Wang; Sreenivas Nannapaneni; Lydia Koenig; Zhengjia Chen; Zhuo Georgia Chen; Yun Yen; Mark E Davis; Dong M Shin
Journal:  J Control Release       Date:  2012-02-08       Impact factor: 9.776

Review 7.  Polyethylene glycol-conjugated copolymers for plasmid DNA delivery.

Authors:  Minhyung Lee; Sung Wan Kim
Journal:  Pharm Res       Date:  2005-01       Impact factor: 4.200

8.  Utilizing Intrinsic Properties of Polyaniline to Detect Nucleic Acid Hybridization through UV-Enhanced Electrostatic Interaction.

Authors:  Partha Pratim Sengupta; Jared N Gloria; Dahlia N Amato; Douglas V Amato; Derek L Patton; Beddhu Murali; Alex S Flynt
Journal:  Biomacromolecules       Date:  2015-09-29       Impact factor: 6.988

9.  DNA detection using water-soluble conjugated polymers and peptide nucleic acid probes.

Authors:  Brent S Gaylord; Alan J Heeger; Guillermo C Bazan
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-07       Impact factor: 11.205

10.  Cationic lipid-coated magnetic nanoparticles associated with transferrin for gene delivery.

Authors:  Xiaogang Pan; Jingjiao Guan; Jung-Woo Yoo; Arthur J Epstein; L James Lee; Robert J Lee
Journal:  Int J Pharm       Date:  2008-03-04       Impact factor: 5.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.